Lithium use and discontinuation in a health maintenance organization

Richard E. Johnson, Bentson McFarland

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Objective: For decades, lithium has been prescribed to treat bipolar disorder. Its efficacy has been documented by clinical trials and by data from specialized clinics. An issue of considerable interest is the use of lithium in managed care systems. This project examined the use of lithium and its continuity of use by enrollees of a health maintenance organization (HMO). Method: In a 6-year longitudinal cohort study, 1,594 lithium users aged 15 years and older who were enrolled in an HMO were followed from 1986- 1991. Data were obtained from automated databases and from medical record review of a random 5% subsample of the group (N=74). Results: Bipolar disorder was the most frequent morbidity treated. Eighty-four percent (N=62 of 74) received services from a psychiatrist. Annual prevalence of lithium use increased over the 6-year period from 1.4 to 2.3 persons per thousand HMO members. Duration of use varied widely with some long-term but many short-term users. Discontinuation of treatment was associated with elevated rates of psychiatric hospitalization and use of psychiatric emergency services. Lithium users were much more likely to receive a variety of other psychotropic drugs than nonusers of the same sex and age. Conclusions: Lithium use in this population was more often sporadic than continuous. Discontinuation of lithium was associated with psychiatric hospitalization. If lithium is to be a cost-effective treatment for bipolar disorder, managed care systems will need to improve adherence to drug treatment regimens.

Original languageEnglish (US)
Pages (from-to)993-1000
Number of pages8
JournalAmerican Journal of Psychiatry
Volume153
Issue number8
StatePublished - Aug 1996

Fingerprint

Health Maintenance Organizations
Lithium
Bipolar Disorder
Psychiatry
Managed Care Programs
Hospitalization
Psychiatric Emergency Services
Psychotropic Drugs
Health Care Costs
Medical Records
Longitudinal Studies
Cohort Studies
Clinical Trials
Databases
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Lithium use and discontinuation in a health maintenance organization. / Johnson, Richard E.; McFarland, Bentson.

In: American Journal of Psychiatry, Vol. 153, No. 8, 08.1996, p. 993-1000.

Research output: Contribution to journalArticle

Johnson, RE & McFarland, B 1996, 'Lithium use and discontinuation in a health maintenance organization', American Journal of Psychiatry, vol. 153, no. 8, pp. 993-1000.
Johnson, Richard E. ; McFarland, Bentson. / Lithium use and discontinuation in a health maintenance organization. In: American Journal of Psychiatry. 1996 ; Vol. 153, No. 8. pp. 993-1000.
@article{bee9c390877941a7ae19ae652007ba5d,
title = "Lithium use and discontinuation in a health maintenance organization",
abstract = "Objective: For decades, lithium has been prescribed to treat bipolar disorder. Its efficacy has been documented by clinical trials and by data from specialized clinics. An issue of considerable interest is the use of lithium in managed care systems. This project examined the use of lithium and its continuity of use by enrollees of a health maintenance organization (HMO). Method: In a 6-year longitudinal cohort study, 1,594 lithium users aged 15 years and older who were enrolled in an HMO were followed from 1986- 1991. Data were obtained from automated databases and from medical record review of a random 5{\%} subsample of the group (N=74). Results: Bipolar disorder was the most frequent morbidity treated. Eighty-four percent (N=62 of 74) received services from a psychiatrist. Annual prevalence of lithium use increased over the 6-year period from 1.4 to 2.3 persons per thousand HMO members. Duration of use varied widely with some long-term but many short-term users. Discontinuation of treatment was associated with elevated rates of psychiatric hospitalization and use of psychiatric emergency services. Lithium users were much more likely to receive a variety of other psychotropic drugs than nonusers of the same sex and age. Conclusions: Lithium use in this population was more often sporadic than continuous. Discontinuation of lithium was associated with psychiatric hospitalization. If lithium is to be a cost-effective treatment for bipolar disorder, managed care systems will need to improve adherence to drug treatment regimens.",
author = "Johnson, {Richard E.} and Bentson McFarland",
year = "1996",
month = "8",
language = "English (US)",
volume = "153",
pages = "993--1000",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "8",

}

TY - JOUR

T1 - Lithium use and discontinuation in a health maintenance organization

AU - Johnson, Richard E.

AU - McFarland, Bentson

PY - 1996/8

Y1 - 1996/8

N2 - Objective: For decades, lithium has been prescribed to treat bipolar disorder. Its efficacy has been documented by clinical trials and by data from specialized clinics. An issue of considerable interest is the use of lithium in managed care systems. This project examined the use of lithium and its continuity of use by enrollees of a health maintenance organization (HMO). Method: In a 6-year longitudinal cohort study, 1,594 lithium users aged 15 years and older who were enrolled in an HMO were followed from 1986- 1991. Data were obtained from automated databases and from medical record review of a random 5% subsample of the group (N=74). Results: Bipolar disorder was the most frequent morbidity treated. Eighty-four percent (N=62 of 74) received services from a psychiatrist. Annual prevalence of lithium use increased over the 6-year period from 1.4 to 2.3 persons per thousand HMO members. Duration of use varied widely with some long-term but many short-term users. Discontinuation of treatment was associated with elevated rates of psychiatric hospitalization and use of psychiatric emergency services. Lithium users were much more likely to receive a variety of other psychotropic drugs than nonusers of the same sex and age. Conclusions: Lithium use in this population was more often sporadic than continuous. Discontinuation of lithium was associated with psychiatric hospitalization. If lithium is to be a cost-effective treatment for bipolar disorder, managed care systems will need to improve adherence to drug treatment regimens.

AB - Objective: For decades, lithium has been prescribed to treat bipolar disorder. Its efficacy has been documented by clinical trials and by data from specialized clinics. An issue of considerable interest is the use of lithium in managed care systems. This project examined the use of lithium and its continuity of use by enrollees of a health maintenance organization (HMO). Method: In a 6-year longitudinal cohort study, 1,594 lithium users aged 15 years and older who were enrolled in an HMO were followed from 1986- 1991. Data were obtained from automated databases and from medical record review of a random 5% subsample of the group (N=74). Results: Bipolar disorder was the most frequent morbidity treated. Eighty-four percent (N=62 of 74) received services from a psychiatrist. Annual prevalence of lithium use increased over the 6-year period from 1.4 to 2.3 persons per thousand HMO members. Duration of use varied widely with some long-term but many short-term users. Discontinuation of treatment was associated with elevated rates of psychiatric hospitalization and use of psychiatric emergency services. Lithium users were much more likely to receive a variety of other psychotropic drugs than nonusers of the same sex and age. Conclusions: Lithium use in this population was more often sporadic than continuous. Discontinuation of lithium was associated with psychiatric hospitalization. If lithium is to be a cost-effective treatment for bipolar disorder, managed care systems will need to improve adherence to drug treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0029788785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029788785&partnerID=8YFLogxK

M3 - Article

C2 - 8678195

AN - SCOPUS:0029788785

VL - 153

SP - 993

EP - 1000

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 8

ER -